LivingGLP1
Descriptive only

Percent body weight change

Type 2 diabetes (adults); background therapy: one or more non insulin glucose lowering drugs

weeks 40 to 104 (target week 68)Not stated by the trialsEach dose separatelyMean differenceSeparate part 2 of a disconnected network
1
Randomized trials
2
Treatments
662
Participants
2
Trial arms

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
SEMA_PO_FLEX_QDSITAGLIPTIN
Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
Baseline effect modifiers and prognostic factors per trial
TrialBaseline BMI or body weight (kg/m2)
effect modifier, prognostic factor; 1 of 1
Sex (percent female)
effect modifier, prognostic factor; 1 of 1
Asian ancestry or region (percent Asian)
effect modifier, prognostic factor; 1 of 1
Kidney function (eGFR) (mL/min/1.73 m2)
prognostic factor, effect modifier; 1 of 1
Treatment duration (weeks)
effect modifier; 1 of 1
Lifestyle co-intervention intensity (none standard intensive)
effect modifier, prognostic factor; 1 of 1
PIONEER 7
S001153
31.1943.4515.0894.36104not_reported

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
  • NoteData handling, input conversions: arms_combined 2
Comparability items per trial
Trialtime weeksanalysis setdefinitioninstrumentadjudicatedproportion methodintercurrent events (discontinuation)intercurrent events (rescue)blindingfundingstart yearEligibility
PIONEER 752randomizednot statednot statednot statednot statednot statednot statedopen_labelindustry2016age 18 or more; HbA1c 7.5 to 9.5 percent; one or two oral glucose lowering drugs

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the mean difference on the analysis scale against the trial's first row. Flags mark converted, combined or approximated inputs.
Trial data entering this analysis
TrialArmTreatmentWeekDataValueSEEvents / NFlagsSource
PIONEER 7A1+A3SEMA_PO_FLEX_QD52arm, percent_change-3.0270.246326arms_combinedregistry:outcomes
PIONEER 7A2+A4SITAGLIPTIN52arm, percent_change-0.7430.237336arms_combinedregistry:outcomes

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab